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Melanoma patients have high frequencies of T cells directed against antigens of their tumor. 
The frequency of these antitumor T cells in the blood is usually well above that of the anti-
vaccine T cells observed after vaccination with tumor antigens. In a patient vaccinated with a 
MAGE-3 antigen presented by HLA-A1, we measured the frequencies of anti-vaccine and 
antitumor T cells in several metastases to evaluate their respective potential contribution to 
tumor rejection. The frequency of anti–MAGE-3.A1 T cells was 1.5 
 
  
 
10
 
 
 
5 
 
of CD8 T cells 
in an invaded lymph node, sixfold higher than in the blood. An antitumor cytotoxic T 
lymphocyte (CTL) recognizing a MAGE-C2 antigen showed a much higher enrichment with a 
frequency of 
 
 
 
10%, 1,000 times higher than its blood frequency. Several other antitumor T 
clonotypes had frequencies 
 
 
 
1%. Similar findings were made on a regressing cutaneous 
metastasis. Thus, antitumor T cells were 
 
 
 
10,000 times more frequent than anti-vaccine T 
cells inside metastases, representing the majority of T cells present there. This suggests that 
the anti-vaccine CTLs are not the effectors that kill the bulk of the tumor cells, but that 
their interaction with the tumor generates conditions enabling the stimulation of large 
numbers of antitumor CTLs that proceed to destroy the tumor cells. Naive T cells appear to be 
stimulated in the course of this process as new antitumor clonotypes arise after vaccination.
 
In Germeau et al. (1), which appears in this issue
of 
 
JEM
 
, we show that metastatic melanoma
patients who receive vaccinations with defined
tumor antigens have high numbers of T cells
directed against tumor antigens other than the
vaccine antigens in their blood. These T cells,
labeled “antitumor,” are found in the blood at
high frequency both before and after vaccina-
tion. This frequency usually vastly exceeds that
of the “anti-vaccine” T cells observed after
several injections of the vaccine. To obtain a
first indication of the respective contributions
of the antitumor T cells and the anti-vaccine T
cells to the tumor rejections that occasionally
occur after vaccination, we set out to evaluate
the presence of both cells in the metastases of a
well-characterized patient.
Metastatic melanoma patient EB81 received
four cutaneous vaccinations with a recombinant
canarypox (ALVAC) virus carrying a minigene
coding for two antigenic peptides encoded by
genes 
 
MAGE-3
 
 and 
 
MAGE-1
 
. These antigenic
peptides are MAGE-3
 
168–176 
 
(MAGE-3.A1) and
MAGE-1
 
161–169 
 
(MAGE-1.A1), and both are
presented by HLA-A1. The ALVAC vaccina-
tions were followed by vaccinations with the
peptides in the absence of adjuvant.
At treatment onset, the patient had 
 
 
 
20
progressing cutaneous metastases in the leg,
including several above 1 cm in diameter (see
Fig. 1). 2 mo after the first vaccination, all of
these metastases began to disappear gradually.
However, a local lymph node started swelling
after 4 mo. It was removed after 7 mo and
found to contain melanoma cells. 1 yr after the
first vaccination, all of the cutaneous metastases
had completely disappeared. The patient has
remained tumor-free for 3 yr.
Before the vaccinations, the frequencies of
anti–MAGE-3.A1 and anti–MAGE-1.A1 CTLs
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in the blood were 
 
 
 
10
 
 
 
7
 
 of CD8 T cells, which is not
higher than those detected in noncancerous individuals. Af-
ter the ALVAC vaccinations, the frequency of anti–MAGE-
3.A1 CTLs rose to a level of 
 
 
 
3 
 
  
 
10
 
 
 
6
 
 of CD8 T cells and
remained in this range during the next year. This response was
quasimonoclonal with 98% of it consisting of CTL clonotype
35. No response against MAGE-1.A1 was observed (2).
A tumor cell line was derived from the cells of the in-
vaded lymph node. As described by Germeau et al. (1), the
use of these cells as stimulators made it possible to detect in
the prevaccination blood a frequency of 3 
 
  
 
10
 
 
 
4
 
 for CTLs
that were capable of lysing specifically the tumor cell line.
The frequency of these antitumor CTLs rose to 3 
 
  
 
10
 
 
 
3
 
 in
postvaccination blood. These CTLs turned out to be di-
rected mainly against antigens encoded by cancer germline
gene 
 
MAGE-C2
 
 and melanocyte differentiation gene 
 
gp100
 
.
CTL clone 16, directed against a MAGE-C2 antigen, had a
frequency of 
 
 
 
10
 
 
 
4
 
 after vaccination, i.e., 30 times higher
than the anti–MAGE-3.A1 CTL 35.
Here we describe the frequency inside various metastases
of anti-vaccine CTL clone 35 and antitumor CTL clone
16. We also present a frequency spectrum of the TCR se-
quences expressed inside metastases collected before and af-
ter vaccinations.
 
RESULTS
Modest enrichment of anti-vaccine T lymphocytes 
in metastases
 
The invaded lymph node of patient EB81, which was re-
moved at a time when most cutaneous metastases had re-
gressed (Fig. 1), presented a large circular area of living tu-
mor cells surrounded by a fibrous shell (Fig. 2 A). There was
also a large area where macrophages loaded with melanin
had accumulated, presumably after destruction of tumor cells
(Fig. 2 D). Such macrophages were also observed at the pe-
riphery of the area of living tumor cells (Fig. 2 C). Thus, it
appeared that a large number of tumor cells had been de-
stroyed in the lymph node, but that many living tumor cells
were still present.
To analyze the frequency of anti–MAGE-3.A1 CTL 35
among the CD8 T cells of this invaded lymph node, we ap-
plied clonotypic PCR amplifications detecting with high
specificity the rearrangements of the sequences coding for
the 
 
  
 
and 
 
  
 
TCR chains of this anti-vaccine CTL clone.
Cryosections of the lymph node, similar to that shown in
Fig. 2 A, were used as sources of RNA. Using a quantitative
PCR for the CD8
 
  
 
sequence, we estimated the number of
CD8 T cells in these sections to be 
 
 
 
26,000 based on an es-
timate of 40 CD8
 
  
 
transcripts per CD8 T cell. Two lymph
node sections out of six provided a positive signal for both
the 
 
  
 
and 
 
  
 
chains of CTL 35, leading to a frequency esti-
mate of 1/64,000 (1.5 
 
  
 
10
 
 
 
5
 
) of the CD8 T cells present in
the invaded lymph node. At the time of resection of the
lymph node, the frequency of CTL 35 in the blood was
 
 
 
2.5 
 
  
 
10
 
 
 
6
 
. Therefore, there was a modest sixfold enrich-
ment in the invaded lymph node.
On a cutaneous metastasis, which showed signs of regres-
sions, a punch biopsy was performed after the fourth AL-
VAC vaccination (Fig. 1). The metastasis still contained tu-
mor cells. The number of CD8
 
  
 
transcripts in the biopsy
was measured by quantitative PCR, leading to an estimate of
 
 
 
30,000 CD8 T cells. The clonotypic PCR for the 
 
  
 
and 
 
 
 
chain of CTL 35 were negative, leading to a frequency esti-
mate below 3 
 
  
 
10
 
 
 
5
 
 CD8 T cells. This excluded that the
anti-vaccine CTLs were more enriched in this metastasis
than in the invaded lymph node.
 
High enrichment of anti–MAGE-C2 CTL 16 in metastases
 
The same approach was used to evaluate the intratumoral
frequency of anti–MAGE-C2 CTL clone 16, an antitumor
CTL that had been found at high frequency in the postvac-
cination blood. All of six sections of the invaded lymph node
gave a positive signal for the clonotypic PCR for both the 
 
 
 
and 
 
  
 
chains. Therefore, we resorted to laser microdissection
to obtain subsections that constituted 
 
 
 
1% of the entire sec-
tion (Fig. 2 A). Most of these also gave a positive signal. This
led to a minimum CTL 16 frequency of 1.7% of the CD8 T
cells present in the region where lymph node architecture
was preserved (Fig. 2, A and D). In the area, which con-
tained living tumor cells, where the density of CD8 T cells
was 
 
 
 
10 times lower, the frequency of CTL 16 was esti-
mated to be 
 
 
 
13% of these CD8 T cells. As CTL 16 was
present in the blood at a frequency of 9 
 
  
 
10
 
 
 
5
 
 CD8 T cells
at the time the metastasis was collected, the enrichment in
the invaded lymph node was 
 
 
 
200 or 
 
 
 
1,500-fold accord-
ing to the region considered.
To reduce the risk of possible technical biases, we con-
firmed this result with an independent approach. RNA
from the invaded lymph node was reverse transcribed using
a primer corresponding to the constant region of the TCR
 
 
Figure 1. Clinical evolution of patient EB81 and timing of vaccinations and blood cell collections. 
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chain. This 
 
  
 
chain cDNA was obtained under conditions
that made it suitable for PCR amplification and cloning.
Thus, a library of TCR
 
  
 
sequences was obtained under
conditions ensuring an unbiased representation of the TCR
 
 
 
sequences present in the invaded lymph node. We se-
quenced 110 clones of this library. 10 of these sequences
turned out to be the 
 
  
 
sequence of CTL 16, leading to a
frequency estimate of 9% of the TCR present in the lymph
node. The ratio of CD4 to CD8 T cells in the node was
 
 
 
2:1, as in the blood. Therefore, the CTL 16 TCR
 
  
 
rep-
resented as much as 27% of the TCR chains of the CD8 T
cells present in this invaded lymph node. Admittedly, this
approach provides proportions of the TCR
 
  
 
transcripts and
not proportions of T cells. And because CTL 16 might have
been in a more activated state than the average CD8 T cell
present in the lymph node, it might have contained a higher
amount of TCR mRNA (3). Nevertheless, even allowing
for a correction by a factor of 10, this approach confirmed
Figure 2. Analysis of the invaded lymph node resected in April 2000. 
(A) Overall structure presented on a cryosection stained with hematoxylin. 
A circular area of living tumor cells (a) is surrounded by a fibrous band (b). 
Above, a crescent-shaped region (c) is devoid of tumor cells. Numerous 
macrophages containing melanin and other inflammatory cells are present 
in this region (see D). The area on the left part of the section (d) represents 
the uninvaded part of the lymph node. The stippled ellipse indicates the 
localization of the area shown in B. The 1-mm holes represent samples 
collected by laser microdissections for gene expression analysis. (B–F) 
Paraffin-embedded sections stained with hematoxylin and (B–D) eosin. 
(B) Higher magnification of an area straddling the living tumor cell region 
and the fibrous band, which is infiltrated with lymphocytes. Macrophages 
containing melanin are located at the outer rim of the tumor cell region. 
The rectangle delineates the area shown in C. (C) Further enlargement of 
the border between tumor cells (1) and the fibrous band, which contains 
macrophages with melanin accumulation (2) and lymphocytes (3). (D) Higher 
magnification of region c (A) with fibroblasts (1), macrophages with melanin 
(brown-colored; 2), lymphocytes (3), and plasmocytes (4). (E and F) Adjacent 
sections treated with anti-CD3 (E) and anti-CD8  antibodies (F). T cells in-
filtrating the tumor are stained in red (immunoperoxidase). Macrophages 
with melanin are brownish. 
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the considerable enrichment of CTL 16 demonstrated by
the first approach.
The TCR
 
  
 
library approach was also applied to the re-
gressing cutaneous metastasis. Out of 228 TCR
 
  
 
sequences
that were obtained, 6 represented the CTL 16 sequence,
indicating a very high enrichment in this metastasis also.
Adjacent to the invaded lymph node, another lymph
node was resected and found to be free of tumor cells.
Quantitative PCR amplification of CD8
 
  
 
sequences and
TCR16
 
  
 
sequences indicated that the proportion of TCR16
mRNA per CD8
 
 
 
 mRNA was 200 times lower in this non-
invaded lymph node relative to the invaded lymph node, in-
dicating little or no enrichment in the noninvaded lymph
node relative to the blood.
 
High frequency of other antitumor T cells in metastases
 
The TCR library approach provided a global view of the fre-
quent TCR mRNA present in the invaded lymph node. Be-
sides CTL 16, several other TCR clonotypes directed against
MAGE-C2 antigens had been identified in the blood of pa-
tient EB81 as described by Germeau et al. (1). These clono-
types were also found to be very frequent in the invaded
lymph node (Table I). Their enrichment relative to the blood
ranged from 150 to 1,000 (Table I). Thus, anti–MAGE-C2
TCR message represented 
 
 
 
20% of the TCR message found
in the invaded lymph node. The TCR sequences of all these
anti–MAGE-C2 clonotypes were also found to be very fre-
quent in the regressing cutaneous metastasis (Table I).
A number of clonotypes directed against other antigens
were also very frequent in the invaded lymph node. A clono-
type directed against a gp100 antigen was present at a frequency
of 0.4% of all TCR. T cell clonotype 101, which had not been
identified after stimulation of blood lymphocytes, was present at
a frequency of 7% (Table I). A CTL clone bearing this TCR
was derived by stimulation with tumor cells of T cells collected
from the invaded lymph node. The target antigen proved to be
a peptide encoded by the gene coding for caseinolytic protease,
which bears a mutation in the tumor, resulting in a new anti-
gen. Several other antitumor clonotypes directed against un-
characterized antigens also had frequencies in the 1% range.
The sets of dominant TCR clonotypes found in the two
metastatic sites collected after vaccination were found to
have considerable overlap. 30 of the 110 TCR sequences
found in the lymph node were also found among the 86
TCR sequences analyzed in the cutaneous metastasis.
 
Ratio of T cells to tumor cells in a cutaneous metastasis
 
Antitumor T lymphocytes are present in metastases at a very
high frequency among the CD8 T cells. But what about
their frequency relative to the tumor cells? In the regressing
cutaneous metastasis, the proportion of tumor cells was eval-
uated visually to be 
 
 
 
75%. An independent evaluation was
made as follows. The melanoma of patient EB81 carries the
BRAF-1 mutation, which is present in most melanomas (4).
Sequencing of PCR amplification products of the tumor cell
line indicated a ratio of mutated to normal sequence of 5:1,
presumably due to gene amplification of the mutated allele.
The same ratio was observed for the encapsulated region of
the invaded lymph node, which, on visual examination, ap-
peared to contain almost only tumor cells. 
 
Table I.
 
Frequency of anti-vaccine and antitumor CD8 T cell clonotypes in the blood and in metastases
 
Before vaccination After vaccination
T cells
 
a
 
Blood
 
b
 
Cutaneous metastasis
 
c
 
Blood
 
d
 
Regressing cutaneous metastasis
 
e
 
Invaded lymph node
 
e
 
Anti–MAGE-3.A1 (Anti-vaccine)
 
168-176
 
 CTL 35
 
 
 
10
 
 
 
7
 
 
 
0.001% 2.5 
 
  
 
10
 
 
 
6
 
 
 
0.003% 0.0015%
Anti–MAGE-C2
 
336–344
 
 
 
CTL 16
 
 
 
7 
 
  
 
10
 
 
 
7
 
 
 
0.001% 9 
 
  
 
10
 
 
 
5
 
3% 9%
 
336–344
 
 CTL 40 4 
 
  
 
10
 
 
 
5
 
0.03% 10 4 1% 2%
191–200 CTL 11 9   10 6 0.1% 3   10 5  0.5% 0.5%
191–200 CTL 41 2   10 6 0.01% 6   10 5 2% 6%
42–50 CTL 1 2   10 5 0.1% 2   10 4 1.5% 6%
Anti-gp100209–217
CTL 7  7   10 7  0.001% 10 4 2% 0.4%
Anti-mutated caseinolytic protease
CTL 101  7   10 7  0.001% 10 4 3% 7%
Other antitumor
CTL 10 4   10 5 3% 8   10 5 1% 0.2%
aAntitumor clonotypes that appeared only after vaccination are in bold. Small numbers define the antigenic peptides.
bFrequencies among CD8 T cells obtained by clonotypic PCR applied to DNA of limiting dilution groups of PBMCs collected in September 1999.
cValues  0.001% are based on a negative clonotypic PCR result performed on cDNA extracted from a fragment of metastasis estimated to contain 105 CD8 T cells. Other values 
represent frequencies of the TCR  chain sequence in the total set of TCR  cDNAs. These values were obtained either by sequencing or by clonotypic PCR.
dFrequencies among CD8 T cells. The value marked by   was obtained by limiting dilution stimulation of PBMCs with peptide. The other values were obtained by clonotypic PCR 
of cDNA obtained from limiting dilution groups of PBMCs collected in March 2000.
eExcept for CTL35 where the frequency was obtained as described in Results, all values represent frequencies of the relevant TCR  chain sequence among the total set of TCR  
cDNAs. These values were obtained either by sequencing or by clonotypic PCR.JEM VOL. 201, January 17, 2005 253
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For the regressing cutaneous metastasis, the ratio was 1.3:1,
leading to the estimate of 42% of tumor cells in this metas-
tasis. Using this estimate and assuming 10 pg total RNA
per tumor cell and 2 pg per normal cell, our sample of 19  g
RNA originated from a piece of metastasis containing  1.5  
106 tumor cells. As stated above, this biopsy was estimated to
contain 30,000 CD8 T cells. The ratio of CD8 T cells to tu-
mor cells was therefore 2%. On the basis of the consider-
ations presented above, antitumor TCR sequences represent
 40% of CD8 TCR sequences in this metastasis. Accord-
ingly, the antitumor T cells therefore amounted to no more
than 0.8% of the tumor cells in the regressing metastasis. The
anti-vaccine T cells amounted to  6   10 7 of tumor cells.
However, the low global ratio of antitumor T cells to tu-
mor cells may have limited relevance because the T cells do
not appear to be distributed at random among the tumor
cells. Instead, they appear to be concentrated on the border
of large compact regions containing tumor cells. For the cu-
taneous metastasis there was such a front of T lymphocytes at
the inner tumor border. A similar concentration of T cells
accompanied by macrophages was also observed on the in-
ner border of the collagen shell located around the tumor
cells in the invaded lymph node (Fig. 2, B and C). Thus, the
local ratio of antitumor T cells to tumor cells in the front
where interaction occurs might be close to 1:1.
Presence of antitumor T cells in metastases before vaccination
Antitumor T cells, including some anti–MAGE-C2, were
already present at a high frequency among the blood lym-
phocytes of patient EB81 before she was vaccinated (Table
I). At that time, the cutaneous metastases of the patient were
clearly progressing. Was this due to a lack of presence of an-
titumor T cells inside these cutaneous metastases? Apparently
not. Anti–MAGE-C2 clonotypes 1, 11, 40, and 41 were
detected in a prevaccination metastasis, albeit at a lower
frequency than in the metastases collected after vaccination
(Table I). But another antitumor CTL was present at a 3%
frequency. Somehow, the antitumor T cells found in the
progressing prevaccination metastasis must have become in-
capable of attacking the tumor cells.
Out of 100 sequences analyzed in a TCR  library de-
rived from the prevaccination metastasis, 17 were also repre-
sented in at least one of the two groups of  100 TCR se-
quences obtained from the two metastatic sites resected after
vaccination. Thus, a number of very frequent antitumor T
cell clonotypes stably occupied the tumor sites, being found
at a high frequency in metastases that were resected at a dis-
tance of several months.
Emergence of new antitumor CTL clonotypes after vaccination
The contrast observed between the very high frequency of
antitumor T cells and the much lower frequency of anti-vac-
cine T cells in the metastases collected after vaccination, sug-
gests the possibility that after vaccination, antitumor T cells
are activated and become the main effectors that eliminate
the tumor cells. This could occur through the reactivation of
T cells that are already present in the tumor or through the
activation of naive antitumor T cell precursors. The latter
implies that new antitumor T cell clonotypes ought to be
detected after vaccination. This is indeed what we observed.
The most frequent anti–MAGE-C2 clonotype found in the
invaded lymph node, namely CTL 16, was not detected
in the blood or in the cutaneous metastasis collected be-
fore vaccination. In addition, the highly frequent anti-gp100
clonotype 7 and clonotype 101 directed against mutated
caseinolytic protease (Table I) were also not detected. But
these findings do not exclude that in addition, previously
present antitumor T cells were reactivated. Moreover, even
though our observations are compatible with the notion that
the anti-vaccine CTLs occasionally promote the stimulation
of new effective antitumor CTLs, they remain short of prov-
ing this point, as it cannot be excluded that new waves of
antitumor clonotypes appear continuously in the natural
course of the disease.
DISCUSSION
What led to the analysis reported here was the observation
that patients who show evidence of tumor regression after
vaccination usually have a very low frequency of anti-vaccine
T cells in the blood. Our results indicate that this paradox ap-
pears to extend to the tumor. In metastases of patient EB81,
including one that clearly regressed, the single responder
CTL clonotype directed against the MAGE-3.A1 vaccine
antigen showed little enrichment relative to the blood. As a
consequence the ratio of these CTLs to tumor cells was as
low as 6   10 7. This reinforces the probability that other
cells might be the main effectors for the regression.
The findings reported here and in Germeau et al. (1)
make a strong case for a possible involvement of T cells di-
rected against tumor antigens other than the vaccine antigen.
Such antitumor T cells were found at high frequencies in the
blood. In patient EB81, who showed a nearly complete tu-
mor response, many of these antitumor T cells were highly
enriched in the metastases. A few dominant T cell clono-
types directed against tumor-specific antigens accounted for
a large fraction, possibly for the majority of the CD8 T cells
present in the metastases after vaccination. Because of the
low proportion of CD8 T cells in the metastases, the global
ratio of the number of antitumor T cells relative to tumor
cells did not exceed 1%, but they appeared to be concen-
trated on certain fronts where this ratio might be close to 1:1.
Finally, we observed after vaccination the appearance of a
wave of new antitumor CD8 T cell clonotypes that were
highly concentrated in the metastases.
These findings made with patient EB81 do not appear to
represent a unique observation. Recently, we have initiated
a similar analysis of a melanoma patient who showed tu-
mor regression after vaccination with the MAGE-3.A1 pep-
tide pulsed on dendritic cells. The findings are very similar.
There is a low frequency of anti-vaccine T cells and there is
a high frequency of antitumor CTLs with high enrichment
in metastases. Remarkably, the most frequent antitumorANTI-VACCINE AND ANTITUMOR CTLS IN MELANOMA METASTASES | Lurquin et al. 254
CTL is also directed against an antigen encoded by MAGE-
C2 (unpublished data).
Antitumor T cells were already present in patient EB81
before vaccination not only in the blood, but also in me-
tastases, where they showed considerable enrichment and
some highly dominant clonotypes. Therefore, the progres-
sion of the tumor before vaccination was not due to a lack of
migration of these T cells into the tumor site. Nor was there
a resistance of the tumor cells due to loss of presentation of
tumor antigens. The metastases regressed after vaccination
and the tumor cell line derived from these metastases was
lysed by the antitumor T cells. Therefore, it appears that at
one point the antitumor T cells became ineffective in the tu-
mor. As these antitumor T cells become active again upon in
vitro restimulation by tumor cells in the presence of cyto-
kines, their inactivation may also be reversible in the tumor.
Many interplaying factors may produce in the tumor a
negative environment that leads to a local paralysis of the an-
titumor T cells. Mechanisms of inhibition of T cells that ap-
pear to be inherent to the functioning of the immune system
have received considerable attention in recent years. Analysis
of mouse systems have demonstrated an inhibitory role for
CD4  CD25  regulatory T cells (5). Recently, a CD4 
CD25  suppressor T cell clone directed against an antigen
encoded by LAGE-1, a cancer germline gene, has been iso-
lated from a melanoma metastasis (6). Another inhibitory
process described in a mouse system involves NK T cells
producing IL-13, which stimulates the production of TGF 
by immature myeloid cells (7). Diversion of the response to-
ward a Th2 cell response with IL-10 could also render the T
cells ineffective against the tumor. TGF  appears to be a
central inhibitory agent (8). The inhibitory processes may
involve positive feedback not only incapacitating the lym-
phocytes, but also rendering them more sensitive to further
inhibitory agents and even transforming them into inhibitory
lymphocytes themselves (9, 10). Indoleamine dioxygenase,
which is produced by tumor cells and dendritic cells, possi-
bly under the influence of regulatory T cells, might play an
important role in inhibiting T cells either in the tumor or in
the draining lymph node by depleting the local tryptophan
supply (11–13). Several other inhibitory factors have been
reported to be released by tumors. It will be very important
to find out which of these mechanisms constitute the main in-
hibitory processes operating in human tumors. Possibly, the
prevailing mechanism may vary from one tumor to another.
How can we envision the process that leads to the rejec-
tion of tumor cells that is observed occasionally after vacci-
nation? We feel that the following, admittedly hypothetical,
sequence of events would be in line with our findings. The
patients would respond to the peptide or ALVAC vaccina-
tion by expanding one or a few CTL clonotypes to a level
below or barely above our present level of detection. In this
regard it is worth remembering that if a single precursor cell
expands 10,000-fold, in our view a significant expansion,
this still leaves its frequency  4   10 7 CD8 T cells, the
global base level frequency of the naive T cells directed
against the antigen (14). Some anti-vaccine T cells would
then be capable of migrating to the tumor. They would re-
sist the immunosuppressive environment for a while. They
would be stimulated by the tumor cells and could destroy a
number of them. This would lead to a local reversion of the
inhibition, probably due to the release of activatory factors
by the stimulated anti-vaccine T cells. This positive environ-
ment would extend focally in a way that might involve a
positive feedback. Activatory factors could render lympho-
cytes less sensitive to the inhibitory factors and might also
block suppressor T cells. As a result, new naive precursors of
antitumor T cells would be activated by the tumor antigens
instead of succumbing under the local suppression as they
did before. Possibly, some antitumor T cells already present
in the tumor, in the activation focus, would also become re-
activated. In the favorable instances, the activated region
would advance slowly throughout the tumor. If this type of
scenario is correct, it might not be the number of CTLs elic-
ited by the vaccine that would be of crucial importance, it
might be their capacity to migrate to the tumor and foremost
to resist to the local inhibitory conditions long enough to be
stimulated by the tumor cells and generate an activation focus.
A process of local activation, similar to the process we
postulate to be triggered by the anti-vaccine CTL, may have
occurred spontaneously at a previous moment in the evolu-
tion of the tumor, generating the high level of antitumor T
cells observed in melanoma patients. It is possible that in the
course of tumor progression, occasional events such as local
inflammation or destruction of some tumor cells create con-
ditions allowing a focal stimulation of antitumor T cells that
eliminate a number of tumor cells. Sometimes the elimi-
nation would be complete, leading to the spontaneous re-
gressions that are observed occasionally with cutaneous
melanoma. In other instances, the regression would be in-
complete because local inhibitory immunological processes
would prevail. Possibly, such immunosurveillance events might
occur repeatedly, leading to the accumulation of successive
waves of antitumor T cells and slowing down tumor pro-
gression. The effect of vaccination would be to trigger one
more such event. All this implies that we vaccinate under
circumstances where a “spent” immunosurveillance process
has left the tumor in a stance of immunological inhibition
that renders the task of the anti-vaccine CTL much more ar-
duous than it would be if previous immunosurveillance pro-
cesses had not occurred (15).
Insofar as the focal release of inhibition by anti-vaccine
T cells promotes the expansion of other antitumor T cell
clones, it could also enable the anti-vaccine T cell clonotype
itself to expand further. This puts into a new light the corre-
lation between detectable anti-vaccine T cell response and
tumor regression, which has been observed on patients vac-
cinated with an ALVAC–MAGE construct (2, 14). Perhaps
this correlation is not due to the fact that only those patients
who make a sizeable T cell response to the vaccine have
enough T cells to successfully attack the tumor. Instead, it
might be due to the fact that only in those patients where aJEM VOL. 201, January 17, 2005 255
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rejection of the tumor is triggered by anti-vaccine T cells
there occurs a further expansion of anti-vaccine T cells,
which raises their frequency above the detection threshold.
On the basis of these considerations, what could be the
reasons for the failure of therapeutic vaccination in a large
majority of the patients? First, there could be a complete lack
of response to the vaccine. The problem could be of a sto-
chastic nature as there may be only a small chance that a CTL
precursor is activated after each injection of the vaccine. We
cannot exclude this possibility, but it is not favored by the ob-
servations of treatment failure in patients who receive a very
large number of vaccinations, whereas some patients respond
after a few. The alternative possibility that some patients may
not have T cell precursors directed against the vaccine is ren-
dered very unlikely by the large number of precursor clo-
notypes for antigen MAGE-3.A1 found in noncancerous
individuals (14). Another possible explanation could be the
overall immunodepression reported in very advanced cancer
patients, but we do not believe that it applies on our group of
patients. In conclusion, we doubt that the complete absence
of response to the ALVAC or peptide vaccine is the major
cause of failure. A second hypothesis is that the limiting factor
is the occurrence of an anti-vaccine T cell that has the re-
quired functional properties to migrate to the tumor, resist
the inhibitory environment of the tumor, and initiate focal
activation. Only a subset of anti-vaccine T cell clones might
have this property and such a T cell clone might not be gen-
erated in most patients by current vaccination procedures.
The response to any given antigen might be “locked” into a
few predominant but unfit clones that prevent others to ap-
pear regardless of how repeatedly one vaccinates. We feel that
this hypothesis deserves careful consideration. A third possi-
bility is that the severity of the intratumoral inhibition varies
considerably from one patient to another and that in the ma-
jority of patients, this level of inhibition would prevent any
anti-vaccine CTL from being effective in the tumor.
A possible remedy for the present lack of success could
be vaccination against several antigens, so that at least one or
two responder T cell clones with proper migration capability
and resistance to inhibitory factors are obtained. A crucial
adjunct to vaccination might be a treatment that alleviates
the immunosuppressive environment of the tumor. One
possible approach is the depletion of some subsets of T cells,
particularly CD4  CD25  suppressor T cells. Recent suc-
cesses of protocols of adoptive therapy preceded by deple-
tion of T lymphocytes by chemotherapy might be due to the
removal of suppressor T cells (16). Another approach could
involve the use of agents counteracting inhibitory factors
such as TGF , indoleamine dioxygenase, and cyclooxygen-
ase 2. In addition, activatory agents such as IFN- , IL-2, and
their combination could be administered not at the time of
vaccination, but later, to increase the resistance of the anti-
vaccine T cells to the negative environment of the tumor.
Our findings have important implications regarding the
possibility of tumor escape from the T cell response induced
by vaccination. The chance that a very small fraction of the
tumor cells lose the expression of the gene that codes for an
antigen targeted by T cell responses appears to be high (17,
18). It is often stated that it is therefore important to vacci-
nate against antigens that the tumor cannot afford to lose,
such as telomerase or various oncogenes. However, if our
findings prove to be general, if successful vaccination in-
volves the induction of many effective T cell clones directed
against several tumor antigens other than the vaccine anti-
gen, then the probability of tumor escape decreases signifi-
cantly and may not be a limiting factor for the success of the
therapeutic vaccination of cancer patients.
MATERIALS AND METHODS
Patients. See Germeau et al. (1) for description of patient and vaccination.
This experimental protocol was approved by the Ethics Review Committee
of the Faculty of Medicine of the Catholic University of Louvain.
Histology. Immunostaining was performed on formalin-fixed paraffin sec-
tions according to the multistep streptavidin–biotin peroxidase system re-
vealed with 3-amino-9-ethylcarbazole. Anti-CD3  polyclonal antibody and
anti-CD8  monoclonal antibody C8/144B were from DakoCytomation.
RNA and DNA extraction. Total RNA was extracted from PBMCs,
frozen samples of metastases, and tumor cryosections with the TriPure reagent
(Roche). 7- m  cryosections were laid on polyethylene-naphtalate mem-
branes and quickly stained with half-diluted RNase-free hematoxylin. RNA
was then extracted from whole sections, parts of sections dissected with a lan-
cet, or smaller areas of  1 mm2 obtained by laser-assisted microdissection and
laser pressure catapulting (P.A.L.M.; Microlaser Technologies AG). RNA
from laser-microdissected fragments was extracted in 200  l TriPure reagent
in the presence of 5 ng synthetic poly-A RNA and 5  g glycogen. For some
tumor sections, which contained a high concentration of melanin, the RNA
was extracted using the RNeasy procedure (QIAGEN), and in these cases,
the reverse transcription was performed in the presence of 1  g/ l bovine se-
rum albumin (Roche). Reverse transcription was applied to all the RNA us-
ing the SuperScript II RNase H  reverse transcriptase (Invitrogen) and an an-
chored oligo(dT)21 primer with a T7 promoter sequence at its 5  end. The
cDNA was then treated with 0.2 U/ l Ribonuclease H (Invitrogen). DNA
was extracted from PBMCs with QIAamp columns (QIAGEN).
Measurement of clonotype frequency in the blood . Clonotypic
PCR was applied on cDNA prepared from groups of 5   104 –106 PBMCs
as described previously (2). The proportion of positive groups for the clo-
notypic PCR and the proportion of CD8 T cells in the PBMCs were used
to estimate the frequency of the CTL clone. The cDNA was used as a tem-
plate for a first low stringency PCR (22 cycles) aimed at amplifying with
certainty all V  and V  products of up to three clonotypes. A set of forward
primers corresponding to all the relevant V  and V  chains was used, with
a reverse primer matching the T7 sequence of the RT primer. A second,
more stringent, PCR amplification (35 cycles) was applied to 1% of the first
product with primers corresponding to the V  and J -C  regions of the
evaluated clonotype. Finally, 0.001% of this product was used for a third
amplification (35 cycles), highly specific for a precise clonotype, usually
with a V primer different from those used in the previous amplifications and
a primer straddling the CDR3/J junction without covering it completely to
check the CDR3 sequence of the amplified product.
Because the RNA of prevaccination PBMCs was found to be degraded,
the frequencies of TCR clonotypes were evaluated by applying PCR to DNA
extracted from 8   106 PBMCs containing 17% of CD8  T cells and ali-
quoted into 192 microwells. A first PCR amplification used a forward V 
primer and a reverse primer matching an intronic sequence downstream to the
relevant J  coding sequence. 1% of this product was used in a second, more
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Measurement of clonotype frequency in tumor samples. A first ap-
proach used 20–30  g RNA extracted from each sample. 1  g was reverse
transcribed and used for the clonotypic PCR described above. The number
of CD8  T cells in these samples was estimated by quantitative PCR for the
CD8  cDNA, using 5 -CTTCTgCATgATCgTCgggA and 5 -ggCCCT-
TCTgggTCTCTg as primers, 6-FAM-5 -CCCACCACTgCCCAgC-
CCAC-TAMRA as probe, and an estimate of 40 CD8  mRNA per cell,
based on our observations with PBMC and CTL clones. A positive clono-
typic PCR indicated that at least one cell of the relevant CTLs was present
among the CD8 T cells present in the sample, namely 1.6   105 CD8 cells
in the prevaccination metastasis and 3   104 CD8 cells in the postvaccina-
tion cutaneous metastasis. When no signal was obtained for the clonotypic
PCR, we considered that fewer than three cells were present, on the basis
of 100 TCR  mRNA per cell or 25 cDNA as the efficiency of reverse
transcription was only 25%. Considering that 1/20 to 1/30 of the RNA was
used for reverse transcription, the average recovery was about one molecule
of TCR  cDNA per CTL.
When a tumor sample was positive for a given clonotype, the nested
clonotypic PCR procedure described above was applied on cDNA ob-
tained from either complete tissue sections or smaller fragments so as to ob-
tain limiting dilution for the relevant clonotype. When all fragments were
positive, we resorted to the evaluation of the frequency of the TCR  se-
quence in a TCR  cDNA library.
TCR  cDNA library. For each library, 1  g total RNA was reverse
transcribed using Powerscript (CLONTECH Laboratories, Inc.) and 1  M
of primer 5 -AgATCTCTgCTTCTgAT matching the C 1 and C 2 se-
quences in the presence of 1  M of the SMART II oligonucleotide
(CLONTECH Laboratories, Inc.). cDNA synthesis was performed in 10  l
according to the manufacturer’s specifications except for the addition of 1.5
 g of T4 gene 32 protein (Roche). When the reverse transcriptase reaches
the 5  end of the TCR  mRNA, it adds a few (dC) nucleotides to the
cDNA. The SMART oligonucleotide contains a poly(G) sequence at its 3 
end, which anneals to this poly(dC) sequence and serves as an extended
template for the reverse transcriptase. The resulting single-stranded cDNA
contains a complete TCR  transcript with a 5  extension that is comple-
mentary to the SMART oligonucleotide. The cDNA was treated with 1 U
Ribonuclease H (Invitrogen), and one tenth was used as a template in a
PCR amplification with an internal sequence of the SMART primer (5 -
gCAgTggTAACAACgCAgAgTA) and a C  primer (5 -CgACCTCggg-
TgggAACA) for 31 cycles with annealing at 60 C. The amplified product
was purified on a sepharose CL-6B size-exclusion column (Amersham Bio-
sciences) and cloned into the pcDNA3.1/V5/His-TOPO plasmid (Invitro-
gen). The constructs were used to transform Escherichia coli TOP10. Se-
quencing indicated that  80% of the cDNA clones represented TCR 
sequences. About 50% of these corresponded to functional TCR  tran-
scripts. The others were either truncated, aberrantly rearranged, or incom-
pletely spliced. About 100 relevant TCR  sequences were obtained from
each library. In addition, 200–800 cDNA clones, depending on the tumor
sample, were screened by clonotypic PCR amplifications under limiting di-
lution conditions.
To confirm or precise the frequencies of some clonotypes, a fraction of
the TCR  cDNA obtained for the library was also amplified by PCR with
the SMART and C  primers. This amplified product was titrated by PCR
for its content of fragments larger than 200 bp and aliquoted into 96 groups
so as to obtain 200 such molecules per group. Clonotypic PCR was applied
to these groups.
Estimation of the number of tumor cells with a BRAF genomic
PCR. A segment of the exon 15 of gene BRAF, containing the V599E
mutation that is frequently present in melanomas (4), was amplified by
PCR, using primers that have been described previously (4), and cloned. A
set of clones were sequenced to establish the proportion of mutated se-
quences. In the lymphoid tissue of the invaded lymph node (Fig. 2 A), only
wild-type sequences (48/48) were found. In the tumoral part of this me-
tastasis, 50/60 (83%) of the sequences were mutated. In the cutaneous me-
tastasis, 32/56 (57%) of the sequences were mutated.
Derivation of CTL clone 101. The TCR  sequence 101, with a V 5.5-
J 2.7 rearrangement, was found repeatedly in the TCR  cDNA library
prepared from the invaded lymph node resected in April 2000. Tumor-
infiltrating lymphocytes from this metastasis were labeled with an anti-CD8
antibody coupled to phycoerythrin and an anti-V 5.5 antibody coupled to
fluorescein (BD Biosciences). The CD8  V 5.5  cells, corresponding to
4% of all CD8 cells, were sorted, cloned by limiting dilution, and stimulated
with irradiated (100 Gy) IFN- –treated (50 U/ml for 48 h; PreproTech)
autologous tumor cells EB81-MEL (5,000 cells/microwell) and irradiated
allogeneic EBV-transformed B cells (LG2-EBV; 50,000 cells/well) in Iscove’s
medium (Life Technologies) supplemented with 10% human serum, 116
mg/L L-arginine, 36 mg/L L-asparagine, 216 mg/L L-glutamine, 100  M
1-methyl-L-tryptophan, 50 U/ml IL-2, 0.5 ng/ml IL-4, and 10 ng/ml IL-7.
The lymphocytes were restimulated each week with tumor cells and feeder
cells, and the resulting T cell clones were screened with a clonotypic PCR
for TCR  101. CTL clone EB81-CTL-734A/1 was obtained, which ex-
pressed TCR  101, and specifically lysed the autologous melanoma cells.
The identification of the antigen recognized by CTL clone 101 will be de-
scribed elsewhere. The antigenic peptide is presented by HLA-A2 mole-
cules and encoded by the casein lytic protease gene, which has undergone a
point mutation in the EB81-MEL cells.
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